Citadel Advisors’s Day One Biopharmaceuticals DAWN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-261,700
| Closed | -$5.61M | – | 13884 |
|
|
2026
Q1 | $5.61M | Buy |
261,700
+73,800
| +39% | +$1.04M | ﹤0.01% | 4160 |
|
|
2025
Q4 | $1.75M | Buy |
+187,900
| New | +$1.57M | ﹤0.01% | 6190 |
|
|
2025
Q3 | – | Sell |
-19,600
| Closed | -$127K | – | 12960 |
|
|
2025
Q2 | $127K | Buy |
19,600
+7,800
| +66% | +$53.7K | ﹤0.01% | 11107 |
|
|
2025
Q1 | $93.6K | Sell |
11,800
-6,600
| -36% | -$71.1K | ﹤0.01% | 11566 |
|
|
2024
Q4 | $233K | Buy |
18,400
+8,800
| +92% | +$122K | ﹤0.01% | 10162 |
|
|
2024
Q3 | $134K | Sell |
9,600
-16,500
| -63% | -$235K | ﹤0.01% | 10705 |
|
|
2024
Q2 | $360K | Buy |
26,100
+10,800
| +71% | +$158K | ﹤0.01% | 8755 |
|
|
2024
Q1 | $253K | Sell |
15,300
-3,000
| -16% | -$44.9K | ﹤0.01% | 9839 |
|
|
2023
Q4 | $267K | Buy |
18,300
+1,400
| +8% | +$17K | ﹤0.01% | 9388 |
|
|
2023
Q3 | $207K | Sell |
16,900
-19,100
| -53% | -$249K | ﹤0.01% | 9837 |
|
|
2023
Q2 | $430K | Sell |
36,000
-16,400
| -31% | -$214K | ﹤0.01% | 8270 |
|
|
2023
Q1 | $701K | Buy |
52,400
+25,800
| +97% | +$504K | ﹤0.01% | 7567 |
|
|
2022
Q4 | $572K | Buy |
+26,600
| New | +$546K | ﹤0.01% | 7965 |
|
|
2022
Q3 | – | Sell |
-57,600
| Closed | -$1.03M | – | 12782 |
|
|
2022
Q2 | $1.03M | Buy |
+57,600
| New | +$595K | ﹤0.01% | 6950 |
|
Other funds holding DAWN
Citadel Advisors's DAWN Position: Q1 2026 in Review
Citadel Advisors sold out of Day One Biopharmaceuticals (DAWN) in Q1 2026, closing a stake of 1,359,613 shares — an estimated $19.2M sold.
Citadel Advisors first reported a position in DAWN in Q1 2022 and held it in 16 quarters. The position peaked at $12.7M in Q4 2025. 208 funds tracked by Wall St. Rank hold DAWN as of Q1 2026.
- Citadel Advisors reported no remaining Day One Biopharmaceuticals position as of Q1 2026 after selling out during the quarter.
- Citadel Advisors sold 1,359,613 Day One Biopharmaceuticals shares in Q1 2026, an estimated $19.2M.
- Citadel Advisors first reported a position in Day One Biopharmaceuticals in Q1 2022 and held it in 16 quarters.
- Citadel Advisors's Day One Biopharmaceuticals position peaked at $12.7M in Q4 2025.
- 208 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.